icon-folder.gif   Conference Reports for NATAP  
41st Meeting of the European Association for the Study of Liver Diseases
Vienna, Austria
April 26-30, 2006
Back grey_arrow_rt.gif
Safety, Tolerability and Antiviral Activity of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 48-Week Analysis of a Phase 2 Study
  Reported by Jules Levin
EASL, April 2006, Vienna, Austria
Lee KS et al. Yonsei University College of Medicine,
Seoul, Korea
Pradefovir (PDV) is a liver-targeted prodrug of PMEA with potentially improved efficacy and less nephrotoxicity than adefovir dipivoxil (ADV).
Pradefovir Phase 2 Study:
Study Objectives

Compare the safety profile of pradefovir 5 mg, 10 mg, 20 mg and 30 mg QD to adefovir 10 mg QD.
Select the dose of pradefovir for the Phase 3 studies.
48 Week Author's Conclusions
- Pradefovir is a highly active, liver targeting prodrug of PMEA
- Significantly more active than adefovir at the registered dose
- Pradefovir, at daily oral doses of 5, 10, 20 and 30 mg per day, is well tolerated (see tables below)
- The safety of pradefovir 30 mg was comparable to adefovir at the registered dose
- The 30 mg dose selected for phase 3 studies
Pradefovir Phase 2 Study: